Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Amgen Analyst Ratings
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $335 to $381
DBS Maintains Amgen(AMGN.US) With Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Remains a Buy on Amgen (AMGN)
Amgen Analyst Ratings
Truist Financial Downgrades Amgen(AMGN.US) to Hold Rating, Announces Target Price $333
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316
Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)
Amgen Analyst Ratings
Barclays Keeps Their Hold Rating on Amgen (AMGN)
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen Analyst Ratings
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362